Mittwoch, 07. Juni 2017, 17:00 - 18:00 iCal
“Functional and structural studies on positive allosteric modulators of ?7 nicotinic receptors”
UZA 2, Seminarraum 2D 313
Althanstraße 14, Pharmaziegebäude, 1090 Wien
The Doctoral Program
ION CHANNELS AND TRANSPORTERS AS MOLECULAR DRUG TARGETS („MolTag“) is pleased to invite you to the following lecture
“Functional and structural studies on positive allosteric modulators of ?7 nicotinic receptors” by Prof.Dr. Hugo R. ARIAS
Center for Research in Molecular Pharmacology, College of Medicine, California Northstate University
on: Wednesday, June 7th, 05:00 pm (17:00)
at: UZA 2, Althanstr. 14, 1090 Vienna, Seminarroom 2D 313
Abstract: Positive allosteric modulators (PAMs) enhance the efficacy of agonists without directly acting on orthosteric, but allosteric, binding sites. We previously characterized the pharmacological activity of three novel PAMs [PAM-2 (3-furan-2-yl-N-p-tolyl-acrylamide), -3 (3-furan-2-yl-N-o-tolyl-acrylamide), and -4 (3-furan-2-yl-N-phenyl-acrylamide)] with high selectivity for the ?7 nicotinic acetylcholine receptor (AChR) (Arias et al., 2011, Biochemistry 50, 5263; Arias et al., 2016, Int. J. Biochem. Cell Biol. 76, 19). Since these compounds reactivate desensitized ?7 AChRs, they were initially classified as type II PAMs (Targowska-Duda et al., 2014; Neurosci. Lett. 569, 126). This classification is supported by macroscopic current studies where the profile of PAM-2 and -4 resemble that of PNU-120596, a type II PAM. However, subsequent single-channel results indicated that the profile of PAM-2 resembles that of 5-hydroxyindole (5-HI) and NS-1738, type I PAMs (Andersen et al., 2016, Neuropharmacology 107, 189). Additional functional studies suggest that PAM-2 enhances peak currents in ?7 AChRs but delays the desensitization of ?7?2 AChRs. The observed activity of PAM-2 on hippocampal ?7* AChRs also supports this dual activity.
The results showing that PAM-2 affects neither the 5-HT3A receptor nor the ?7/5-HT3A chimera suggest that the active site for PAM-2 is located neither at the extracellular domain nor at the junctional domain comprising the pre-M1 and M2-M3 loop (Andersen et al., 2016). The results showing that the quintuple ?7 mutant (i.e., S223T/A226S/M254L/I281M/V288F) is sensitive neither to PAM-2 nor PNU-120596, but to 5-HI and NS-1738, support the view that the active site of PAM-2 overlaps the PNU-120596 intrasubunit pocket. Additional docking studies suggest that PAM-2 binds to an intersubunit locus using the ?7?2 model. In other words, it seems that the potentiating effect of PAM-2 is elicited by interaction with the intrasubunit pocket, whereas the decreased desensitization effect is elicited by binding to the intersubunit locus.
Passive avoidance test results indicated that PAM-2 enhances memory acquisition (1 mg/kg) and memory consolidation (0.5-2 mg/kg), in an ?7-selective manner, and that an inactive dose of DMXBA, a selective ?7 agonist, enhances the activity elicited by an inactive dose (0.1 mg/kg) of PAM-2, suggesting synergistic interaction (Targowska-Duda et al., 2016; Behav. Brain Res. 302, 142). Using the set-shifting task test, it was also demonstrated that PAM-2 enhances cognitive flexibility in an ?7-selective manner, and increases the activity observed for selective ?7-agonists (Potasiewicz et al., 2015, Br. J. Pharmacol. 172, 5123). Forced swimming tests indicated that PAM-2 has antidepressant-like activity (Targowska-Duda et al., 2014; Arias et al., 2015, Neurochem. Int. 87, 110).
Biochemical studies indicated that the chronic treatment (21 days) with PAM-2 up-regulates ?7 AChRs and increases Erk1/2 phosphorylation in the hippocampus but not in the cortex (Targowska-Duda et al., 2016). In addition, PAM-2 enhances nicotine-induced release of dopamine and GABA, and 5-HT, but not ACh, in the nucleus accumbens. These results suggest that PAM-2 provokes a myriad of neurochemical effects that can be translated into the observed behavioral outcomes.
In conclusion, novel ?7 PAMs might be used for the development of therapies for cognitive impairment and depression-related diseases.
Contact: Doctoral Program MolTag, Dept. of Pharmacology and Toxicology; moltag.univie.ac.at, Office.firstname.lastname@example.org
Department of Pharmacology and Toxicology
DK Molecular Drug Targets
01 5277 55320
Erstellt am Mittwoch, 26. April 2017, 14:06
Letzte Änderung am Donnerstag, 27. April 2017, 08:25